Oppenheimer analyst Michael Wiederhorn raised his price target for UnitedHealth to $343 from $312 following quarterly results. The analyst maintains an Outperform rating on the shares as UnitedHealth continues to produce "strong results," and notes that he would not be surprised to see the other insurers follow suit.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here